FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2558049074> ?p ?o ?g. }

• W2558049074 abstract "Abstract Abstract 251 Literature review and TACL experience support an expected less than 40% complete remission rate with variety of regimens in patients with ALL in second and subsequent relapse (Ko, J Clin Oncol 2010; 28: 648–654). We had shown that bortezomib might be safely combined with vincristine, dexamethasone, pegylated asparaginase, and doxorubicin (VXLD) in the phase I portion of our study (Messinger, Pediatr Blood Cancer 2010;55:254–9). We now report the phase II expansion of that study. ALL patients who relapsed or were refractory after 2 or 3 regimens were treated with bortezomib 1.3 mg/m2/dose on days 1, 4, 8 and 11, combined with VXLD. Patients between ages 1 to 21 years old, with more than 25% bone marrow blasts, were eligible. One patient from the phase I cohort with these criteria was included in the phase II extension. In the phase II extension 22 patients were treated with this combination and all are included in analyses. All patients had relapsed or failed at least 2 prior regimens. Overall 14 achieved complete remission (CR; M1 marrow with ANC and platelet recovery and no extramedullary disease or circulating blasts) and 2 achieved CRp (CR with no platelet recovery) for total 73% remission rate (Table). This level of response exceeded the predefined criteria, allowing for early termination of the study. Three patients (14%) died from bacterial infections and two patients (9%) had no response (Table). One patient (4.5%) was not evaluable for response due to protocol violation, when additional therapy was administered before CR was confirmed with peripheral blood count recovery. B-Lineage ALL patients fared best, with 16/20 achieving CR + CRp (overall response rate 80%), whereas the two patients with T-cell ALL did not respond. Similarly, B-Lineage ALL had superior bone marrow response (M1 marrow): B-Lineage = 17/20 (85%) vs. T-cell = 0/2 (0%). Severe grade 3 or more peripheral neuropathy (PN) was seen in 2 (9%) patients, (one had prior vincristine PN). One patient has developed mucor invasive sinus and orbital infection, requiring halting therapy after day 14 but achieved CRp. After the 3 (14%) septic deaths, the use of vancomycin, levofloxacin and voriconazole or posaconazole prophylaxis in the last 6 patients has prevented further infectious mortality.ResponseAllBTn22202CR14 (64%)14 (70%)0CRp2 (9%)2 (10%)0Total Response16 (73%)16 (80%)0Deaths3 (14%)3 (15%)0SD/PD2 (9%)02 (100%)N/E1 (4.5%)1 (5%)0 In conclusion, the regimen of bortezomib + VXLD is exceptionally effective in multiple relapsed B-Lineage ALL with the highest response rate for any multiply relapsed ALL trial reported thus far. The use of prophylactic antibiotics may be effective in reducing mortality. Bortezomib with VXLD should be further evaluated in randomized fashion on frontline relapse and high-risk pediatric B-Lineage ALL clinical studies. Disclosures: Messinger: Genzyme: Consultancy. Off Label Use: Bortezomib (Velcade®) is approved for multiple myeloma and mantle cell lymphoma both B cell malignancies. We are describing use in relapsed B cell Acute Lymphoblastic Leukemia which is off label.”" @default.
• W2558049074 created "2016-12-08" @default.
• W2558049074 creator A5003133060 @default.
• W2558049074 creator A5022866833 @default.
• W2558049074 creator A5032005310 @default.
• W2558049074 creator A5033167405 @default.
• W2558049074 creator A5047701227 @default.
• W2558049074 creator A5060869564 @default.
• W2558049074 creator A5083018211 @default.
• W2558049074 date "2011-11-18" @default.
• W2558049074 modified "2023-10-02" @default.
• W2558049074 title "Bortezomib Combined with VXLD Chemotherapy Is Highly Effective In Advanced B-Lineage Acute Lymphoblastic Leukemia Allowing Early Study Termination Due to Efficacy. A Therapeutic Advances in Childhood Leukemia (TACL) Consortium Phase II Study" @default.
• W2558049074 doi "https://doi.org/10.1182/blood.v118.21.251.251" @default.
• W2558049074 hasPublicationYear "2011" @default.
• W2558049074 type Work @default.
• W2558049074 sameAs 2558049074 @default.
• W2558049074 citedByCount "3" @default.
• W2558049074 countsByYear W25580490742012 @default.
• W2558049074 countsByYear W25580490742020 @default.
• W2558049074 crossrefType "journal-article" @default.
• W2558049074 hasAuthorship W2558049074A5003133060 @default.
• W2558049074 hasAuthorship W2558049074A5022866833 @default.
• W2558049074 hasAuthorship W2558049074A5032005310 @default.
• W2558049074 hasAuthorship W2558049074A5033167405 @default.
• W2558049074 hasAuthorship W2558049074A5047701227 @default.
• W2558049074 hasAuthorship W2558049074A5060869564 @default.
• W2558049074 hasAuthorship W2558049074A5083018211 @default.
• W2558049074 hasConcept C121332964 @default.
• W2558049074 hasConcept C126322002 @default.
• W2558049074 hasConcept C141071460 @default.
• W2558049074 hasConcept C142424586 @default.
• W2558049074 hasConcept C143998085 @default.
• W2558049074 hasConcept C2776364478 @default.
• W2558049074 hasConcept C2776694085 @default.
• W2558049074 hasConcept C2776755627 @default.
• W2558049074 hasConcept C2777478702 @default.
• W2558049074 hasConcept C2778336483 @default.
• W2558049074 hasConcept C2778461978 @default.
• W2558049074 hasConcept C2779429289 @default.
• W2558049074 hasConcept C2780007613 @default.
• W2558049074 hasConcept C2780401358 @default.
• W2558049074 hasConcept C31760486 @default.
• W2558049074 hasConcept C71924100 @default.
• W2558049074 hasConcept C87355193 @default.
• W2558049074 hasConcept C90924648 @default.
• W2558049074 hasConceptScore W2558049074C121332964 @default.
• W2558049074 hasConceptScore W2558049074C126322002 @default.
• W2558049074 hasConceptScore W2558049074C141071460 @default.
• W2558049074 hasConceptScore W2558049074C142424586 @default.
• W2558049074 hasConceptScore W2558049074C143998085 @default.
• W2558049074 hasConceptScore W2558049074C2776364478 @default.
• W2558049074 hasConceptScore W2558049074C2776694085 @default.
• W2558049074 hasConceptScore W2558049074C2776755627 @default.
• W2558049074 hasConceptScore W2558049074C2777478702 @default.
• W2558049074 hasConceptScore W2558049074C2778336483 @default.
• W2558049074 hasConceptScore W2558049074C2778461978 @default.
• W2558049074 hasConceptScore W2558049074C2779429289 @default.
• W2558049074 hasConceptScore W2558049074C2780007613 @default.
• W2558049074 hasConceptScore W2558049074C2780401358 @default.
• W2558049074 hasConceptScore W2558049074C31760486 @default.
• W2558049074 hasConceptScore W2558049074C71924100 @default.
• W2558049074 hasConceptScore W2558049074C87355193 @default.
• W2558049074 hasConceptScore W2558049074C90924648 @default.
• W2558049074 hasLocation W25580490741 @default.
• W2558049074 hasOpenAccess W2558049074 @default.
• W2558049074 hasPrimaryLocation W25580490741 @default.
• W2558049074 hasRelatedWork W1616474014 @default.
• W2558049074 hasRelatedWork W2129168184 @default.
• W2558049074 hasRelatedWork W2166628031 @default.
• W2558049074 hasRelatedWork W2406938253 @default.
• W2558049074 hasRelatedWork W2461224295 @default.
• W2558049074 hasRelatedWork W2536327780 @default.
• W2558049074 hasRelatedWork W2548587676 @default.
• W2558049074 hasRelatedWork W2553785572 @default.
• W2558049074 hasRelatedWork W2565395380 @default.
• W2558049074 hasRelatedWork W2567298681 @default.
• W2558049074 hasRelatedWork W2572092593 @default.
• W2558049074 hasRelatedWork W2589503393 @default.
• W2558049074 hasRelatedWork W2590777883 @default.
• W2558049074 hasRelatedWork W2590885898 @default.
• W2558049074 hasRelatedWork W2591001182 @default.
• W2558049074 hasRelatedWork W279331096 @default.
• W2558049074 hasRelatedWork W2911669613 @default.
• W2558049074 hasRelatedWork W2979743524 @default.
• W2558049074 hasRelatedWork W2980961035 @default.
• W2558049074 hasRelatedWork W3023619619 @default.
• W2558049074 isParatext "false" @default.
• W2558049074 isRetracted "false" @default.
• W2558049074 magId "2558049074" @default.
• W2558049074 workType "article" @default.